| |
SPDR S&P Biotech (XBI) |
Powershares Dynamic Biotech & Genome Portfolio (PBE) |
First Trust Amex Biotechnology (FBT) |
iShares Nasdaq Biotechnology (IBB) |
Biotech HOLDRs (BBH)
|
| Price ($) |
$58.75 |
$19.45 |
$25.70 |
$84.01 |
$176.95
|
| Year-to-Date Return (%) |
27.3 |
9.9 |
9.2 |
8.0 |
-3.7
|
| Number of Stocks |
31 |
30 |
20 |
170 |
15
|
| How Stocks are Weighted |
Equally |
Proprietary |
Equally |
Market cap |
Market cap
|
| Top Three Holdings |
Myriad Genetics, Cepheid, Pharmion |
Imclone Systems, Gilead Sciences, Amgen |
Vertex Pharmaceuticals, Biogen, Celgene |
Amgen, Gilead Sciences, Celgene |
Genentech, Amgen, Gilead Sciences
|
| Top Three as a % |
9.7 |
16.2 |
18.1 |
24.1 |
74.0
|
| Avg. Market Cap ($billions) |
9.6 |
12.5 |
14.3 |
2.1 |
16.7
|
| Comments |
This index starts with every biotech in the S&P universe, then trims the list based on market cap and trading volume. |
Powershares uses its own "Intellidex," choosing stocks by such criteria as growth rate, risk, and valuation. |
With FBT, you know what you're getting: 20 top biotech stocks with very little turnover. |
The clear leader in trading volume, iShares contains nearly every biotech-related stock in the NASDAQ. |
This portfolio is never reweighted, and its stock holdings rarely change. |
Copyright 2007, by The McGraw-Hill Companies Inc. All rights reserved.
